Informational letter addressed to healthcare professionals on the safety of the use of the medicinal products AVODART and DUODART. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

04.12.2025 567 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарських засобів АВОДАРТ та ДУОДАРТ. Лікарські засоби, що містять фінастерид (finasteride) та дутастерид (dutasteride): нові заходи щодо мінімізації ризику суїцидальних думокPDF · 1.7 МБ

Завантажити

Informational letter addressed to healthcare professionals on the safety of the use of the medicinal products AVODART and DUODART. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter addressed to healthcare professionals on the safety of the use of the medicinal products AVODART and DUODART. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration